Literature DB >> 18542099

CD1d presentation of glycolipids.

Anneliese O Speak1, Vincenzo Cerundolo, Frances M Platt.   

Abstract

The CD1 family of antigen-presenting molecules consists of five members, CD1a to e. Of these molecules CD1d has been the subject of much interest over the past 10 years following the discovery that this molecule presents antigens to a group of T cells known as invariant natural killer T cells (iNKT). iNKT cells carry an invariant T cell receptor which contains homologous gene segments in mouse and man. iNKT cells are positively selected in the thymus in the same manner as major histocompatibility complex restricted T cells, except iNKT cells require CD1d to be presented by thymocytes rather than epithelial cells. Once in peripheral organs, iNKT cells appear to play multiple roles in host defence against pathogens and cancer. If the numbers of iNKT cells are not correctly regulated it can result in autoimmune disorders, such as diabetes. The ligands for iNKT cells have been the subject of much research but identifying physiologically relevant candidate ligands for positive selection or activation has proved technically very challenging. This is largely due to the fact that the ligands for iNKT cells are lipids. The lipid ligands for thymic selection and some of those involved in peripheral activation are self-derived. Glycosphingolipids are suggested to be the class of lipid for iNKT cell thymic development. For peripheral activation it appears multiple classes of self-derived lipids may play a role, in addition to pathogen-derived lipids. This review will cover essential background to iNKT cell and CD1d biology with emphasis on the candidate iNKT cell ligands proposed to date.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18542099     DOI: 10.1038/icb.2008.42

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  7 in total

1.  Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

Authors:  Mayrel Labrada; Isabel Pablos; Francesca Prete; Giselle Hevia; Marilyn Clavell; Federica Benvenuti; Luis E Fernández
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  CD1d gene is a target for a novel amplicon at 1q22-23.1 in human hepatocellular carcinoma.

Authors:  Shi-Guang Zhang; Wen-Qin Song; Ying-Tang Gao; Bin Yang; Zhi Du
Journal:  Mol Biol Rep       Date:  2010-01       Impact factor: 2.316

3.  STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis.

Authors:  Abhirami K Iyer; Jianyun Liu; Richard M Gallo; Mark H Kaplan; Randy R Brutkiewicz
Journal:  Immunology       Date:  2015-09-21       Impact factor: 7.397

4.  Alpha versus beta: are we on the way to resolve the mystery as to which is the endogenous ligand for natural killer T cells?

Authors:  Y Ilan
Journal:  Clin Exp Immunol       Date:  2009-09-30       Impact factor: 4.330

5.  Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.

Authors:  Sarah E Rzemieniak; Aaron F Hirschfeld; Rachel E Victor; Mark A Chilvers; Dongjun Zheng; Peter van den Elzen; Stuart E Turvey
Journal:  Immunology       Date:  2010-01-19       Impact factor: 7.397

Review 6.  Immune dysfunction in Niemann-Pick disease type C.

Authors:  Nick Platt; Annelise O Speak; Alexandria Colaco; James Gray; David A Smith; Ian M Williams; Kerri-Lee Wallom; Frances M Platt
Journal:  J Neurochem       Date:  2015-06-04       Impact factor: 5.372

7.  Invariant natural killer T cells are not affected by lysosomal storage in patients with Niemann-Pick disease type C.

Authors:  Anneliese O Speak; Nicholas Platt; Mariolina Salio; Danielle te Vruchte; David A Smith; Dawn Shepherd; Natacha Veerapen; Gurdyal S Besra; Nicole M Yanjanin; Louise Simmons; Jackie Imrie; James E Wraith; Robin H Lachmann; Ralf Hartung; Heiko Runz; Eugen Mengel; Michael Beck; Christian J Hendriksz; Forbes D Porter; Vincenzo Cerundolo; Frances M Platt
Journal:  Eur J Immunol       Date:  2012-06-14       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.